Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195104 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00195104 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 87 participants.
The verdict
NCT00195104, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
Interventions
- DRUG Cytarabine
- DRUG Arsenic Trioxide (Tricenox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2003-09-17 |
| Est. Completion | 2006-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195104
The ClinicalTrials.gov registry entry for NCT00195104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00195104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195104 about?
NCT00195104 is a clinical study titled "Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML". The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
What is the current status of trial NCT00195104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2003-09-17. Estimated completion is 2006-06-20.
What interventions are being tested in trial NCT00195104?
The interventions under investigation include: Cytarabine (DRUG), Arsenic Trioxide (Tricenox) (DRUG).
Who is sponsoring clinical trial NCT00195104?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.